OMCL · Omnicell, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP EBITDA non-GAAP | 111.88M | Six Months Ended June 30 | — |
|
|
|||
| Non-GAAP EBITDA margin non-GAAP | 18% | Six Months Ended June 30 | — |
| Non-GAAP free cash flow non-GAAP | 94.42M | Six Months Ended June 30 | — |
| Non-GAAP gross margin non-GAAP | 48.1% | Six Months Ended June 30 | — |
| Non-GAAP operating margin non-GAAP | 13.5% | Six Months Ended June 30 | — |
| Non-GAAP product gross margin non-GAAP | 49.2% | Six Months Ended June 30 | — |
| Non-GAAP product gross profit non-GAAP | 92.06M | Three Months Ended June 30, 2026 | — |
| Non-GAAP service gross margin non-GAAP | 46.6% | Six Months Ended June 30 | — |
| Annual Recurring Revenue | 635.56M | December 31, 2025 | — |
| Long-term product backlog | 205.15M | December 31, 2025 | — |
| Product bookings | 535M | year ended December 31, 2025 | — |
| Short-term product backlog | 435.15M | December 31, 2025 | — |
| Total product backlog | 640.3M | December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OMCL
this stock
Omnicell, Inc.
|
$1.64B | -19.6% | +10.5% | 42.9 | 7.6% |
|
VEEV
Veeva Systems Inc
|
$39.43B | +12.4% | +28.1% | 43.0 | 4.5% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$13.02B | -24.9% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.77B | +58.4% | +28.2% | 36.1 | 4.2% |
|
TEM
Tempus AI, Inc.
|
$8.91B | +3.7% | +83.4% | — | 18.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OMCL | -1.9% | -10.8% | -13.1% | +3.0% | -19.6% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | -1.5% | -13.7% | -24.7% | +0.1% | -32.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.